An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A pharmacy called Apothecary Pharma has recalled some compounded batches of tirzepatide and NAD+ that it made. A recall means the company is asking customers and clinics to stop using those specific products and return them or dispose of them. The short notice didn’t say every product from the pharmacy is affected — it refers to particular compounded lots — and it didn’t give a detailed public reason in the snippet you saw. Tirzepatide is a medicine that has been in the news because versions of it are used for diabetes and weight loss. In simple terms, it acts like two gut hormones that help control blood sugar and reduce appetite; that’s why commercial drugs with similar actions have brand names you may have heard of. NAD+ (nicotinamide adenine dinucleotide) is a molecule our cells use for basic energy and repair processes, and some clinics offer “NAD+ infusions” or injections as a wellness treatment, though that’s not the same as a standard approved drug. “Compounded” means the pharmacy mixed or made these preparations specifically for certain patients or clinics rather than selling a factory-made, approved drug. The short report you shared doesn’t include study results — this is a safety recall, not a research finding. So there’s no new claim about these products working better or worse. What we know from the notice is limited: specific compounded lots are being pulled. The snippet doesn’t say whether the recall was because of contamination, incorrect potency (too much or too little active ingredient), labeling mistakes, or some other manufacturing problem. There’s also no information there about any reported injuries or how many doses are affected. Why this matters: tirzepatide-type medicines and NAD+ therapies are being used more widely, sometimes outside standard hospitals, so problems with how they’re made can affect a lot of people. If you or your clinic got a compounded tirzepatide or NAD+ product from this pharmacy, you should check the recall notice and follow its instructions. Using a compromised product could mean you don’t get the expected benefit, or worse, you could be exposed to contamination or incorrect dosing. For people on prescribed diabetes or weight-loss regimens, switching products or skipping doses without medical advice can be risky. Caveats and risks: compounded drugs aren’t regulated in exactly the same way as factory-made, FDA-approved drugs, which can increase variability in quality. A recall doesn’t automatically mean harm occurred, but it does indicate the manufacturer found a problem or regulators did. If you have received an affected product, contact the dispensing clinic or the pharmacy for guidance and talk to your healthcare provider before making any changes to treatment. Also note that some uses of NAD+ are offered as wellness services rather than evidence-based medical treatments; those practices have their own uncertain benefits and risks. Bottom line: A recall means stop using the specified compounded tirzepatide and NAD+ from Apothecary Pharma until you get clear instructions; check with your provider for safe next steps.
Source: American Spa